# A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

> **NCT00256204** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 1174 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Rasagiline Mesylate
- **DRUG:** Rasagiline Mesylate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00256204
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-04
- **Final completion:** 2009-06
- **Target enrollment:** 1174 (ACTUAL)
- **Last updated:** 2012-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256204, "A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00256204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*